Sponsored Links
| Alpharadin Significantly Improves Overall Survival In Phase III In Patients With Castration-Resistant Prostate Cancer That Has Spread To The Bone |
 |
 |
 |
| Medical News - Orthopaedics | |||
|
Bayer Healthcare today announced that the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial evaluating Bayer's investigational compound Alpharadin (radium-223 chloride), which is exclusively licensed from Algeta ASA, in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases met its primary endpoint by significantly improving overall survival... Read more: Bones / Orthopedics News From Medical News Today
|